---
title: "UBS Remains a Hold on arGEN X (0QW0)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295175089.md"
description: "In a report released yesterday, Xian Deng from UBS maintained a Hold rating on arGEN X. The company’s shares closed last Wednesday at €753.80.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks According to TipRanks, Deng is ranked #1319 out of 12376 analysts. Currently, the analyst consensus on arGEN X is a Strong Buy with an average price target of €932.00."
datetime: "2026-08-07T03:15:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295175089.md)
  - [en](https://longbridge.com/en/news/295175089.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295175089.md)
generator: "portal-rs"
---

# UBS Remains a Hold on arGEN X (0QW0)

In a report released yesterday, Xian Deng from UBS maintained a Hold rating on arGEN X. The company’s shares closed last Wednesday at €753.80.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Deng is ranked #1319 out of 12376 analysts.

Currently, the analyst consensus on arGEN X is a Strong Buy with an average price target of €932.00.

### Related Stocks

- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)

## Related News & Research

- [RBC Capital Keeps Their Buy Rating on arGEN X (0QW0)](https://longbridge.com/en/news/296296197.md)
- [argenx (ENXTBR:ARGX) Hits A Phase 3 Win, Is The Upside Fully Priced?](https://longbridge.com/en/news/296529685.md)
- [$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296119451.md)
- [These Analysts Boost Their Forecasts On Argenx](https://longbridge.com/en/news/296226998.md)
- [Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint](https://longbridge.com/en/news/296059044.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**